Yearly Archives: 2024

/2024

MHRA Class 3 Medicines Recall: Atomoxetine 10mg, 18mg, 25mg, 40mg Capsules (Neuraxpharm UK Ltd)

Class 3 Medicines Recall: Atomoxetine 10mg, 18mg, 25mg, 40mg Capsules (Neuraxpharm UK Ltd) Drug alert number: EL (24)A/19 Date issued: 5 June 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 3 medicines recall for: Atomoxetine 10mg, 18mg, 25mg, 40mg Capsules (Neuraxpharm UK Ltd) Company name: Neuraxpharm UK Ltd Product name: Atomoxetine [...]

The post MHRA Class 3 Medicines Recall: Atomoxetine 10mg, 18mg, 25mg, 40mg Capsules (Neuraxpharm UK Ltd) appeared first on Community Pharmacy England.

By |June 5th, 2024|Lexpos News|Comments Off on MHRA Class 3 Medicines Recall: Atomoxetine 10mg, 18mg, 25mg, 40mg Capsules (Neuraxpharm UK Ltd)

Reminder: GP Connect: Update Record rollout

GP Connect: Update Record is a new feature that CPCF IT system suppliers are adding to their systems, with Cegedim and Positive Solutions already live. Update Record allows information about patient consultations outside of general practice to be shared safely with general practice, so the information can be updated in the patient record. The messages [...]

The post Reminder: GP Connect: Update Record rollout appeared first on Community Pharmacy England.

By |June 5th, 2024|Lexpos News|Comments Off on Reminder: GP Connect: Update Record rollout

CPCF negotiations during the election period

We have issued the following clarification on the 2024/25 Community Pharmacy Contractual Framework (CPCF) negotiations. Our Chief Executive Janet Morrison said: “Government purdah effectively began as soon as the Prime Minister announced the General Election. Whilst discussions can continue no formal agreement can be reached until after the election and new Ministers are appointed. Current [...]

The post CPCF negotiations during the election period appeared first on Community Pharmacy England.

By |June 3rd, 2024|Lexpos News|Comments Off on CPCF negotiations during the election period

Drospirenone (Slynd®) 4mg tablets re-classified as a special container

Following representations from Community Pharmacy England, the Department of Health of Social Care (DHSC) has re-determined the special container status of Drospirenone (Slynd®) 4mg tablets. From 1 June 2024, Drospirenone (Slynd®) 4mg tablets were re-classified as a special container at sub-pack level (sub-pack of 28) as they meet the relevant criteria as set out in Part II [...]

The post Drospirenone (Slynd®) 4mg tablets re-classified as a special container appeared first on Community Pharmacy England.

By |June 3rd, 2024|Lexpos News|Comments Off on Drospirenone (Slynd®) 4mg tablets re-classified as a special container

MHRA Class 4 Medicines Defect Information: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.)

Class 4 Medicines Defect Information: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.) Drug alert number: EL (24)A/18 Date issued: 03 June 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.) Company name: Manx Healthcare Ltd. Product name: Betamethasone Valerate [...]

The post MHRA Class 4 Medicines Defect Information: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.) appeared first on Community Pharmacy England.

By |June 3rd, 2024|Lexpos News|Comments Off on MHRA Class 4 Medicines Defect Information: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.)